The discussion around Paxlovid continues as users share their personal experiences and opinions regarding its effectiveness in treating COVID-19. While some commend the drug for significantly reducing symptom intensity and its potential to prevent long COVID, others express concerns over its high cost and the limited data on its efficacy, particularly outside of the initial study. The imperative for negative results publication is also highlighted, paralleling the need for transparency in medical research. Positive anecdotal evidence from various users emphasizes the value of Paxlovid in improving the quality of life during infection, but the interplay between individual health metrics and drug efficacy raises questions about its universal effectiveness. Overall, Paxlovid appears to remain a clinically relevant option, especially for high-risk populations, despite the ongoing debate regarding its cost versus benefits.